TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16752186
Drug: Relationship between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relationship between adiponectin and insulin sensitivity
Study: 11291551
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg three times daily for 10 days
Study: 11291551
Drug: Acyclovir 800
Normalized name: acyclovir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 800 mg five times daily for 10 days
Study: 9725757
Drug: lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (2 mg) and oxazepam (30 mg)
Study: 7986772
Drug: Combined amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined amphetamine (0.3 mg/kg) with haloperidol (2 mg)
Study: 7986772
Drug: Amphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine (0.3 mg/kg)
Study: 5296380
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment with isoniazid plus PAS
Study: 5296380
Drug: Sanatorium treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanatorium treatment with isoniazid plus PAS
Study: 23064079
Drug: Bupropion (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (75 mg twice a day for 7 days)
Study: 21535995
Drug: Olanzapine 5-10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5-10 mg/d
Study: 21535995
Drug: Olanzapine 2.5
Normalized name: olanzapine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 2.5 mg/d
Study: 8290661
Drug: Venlafaxine 150-200
Normalized name: venlafaxine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 150-200 mg/day
Study: 8290661
Drug: Venlafaxine 50-75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 50-75 mg/day
Study: 8290661
Drug: Venlafaxine 25
Normalized name: venlafaxine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 25 mg/day
Study: 28166751
Drug: Generic pamphlet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic pamphlet on colorectal cancer treatment (Control group).
Study: 16245914
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection
Study: 16245914
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (western medicine only)
Study: 12044376
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous fluids in accordance with hospital practice (> or = 3 L water and 154 mmol sodium per day)
Study: 12044376
Drug: Restricted intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted intake (< or = 2 L water and 77 mmol sodium per day)
Study: 12044376
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous fluids in accordance with hospital practice
Study: 2665554
Drug: 1.7 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g/kg alcohol drink on Days 1-4, placebo on Day 5
Study: 627302
Drug: Floctafenine (Idarac)
Normalized name: floctafenine
DrugBank: Floctafenine (DB08976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floctafenine (Idarac) 200 mg four times daily
Study: 627302
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg four times daily
Study: 28454795
Drug: Serial human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serial human antimurine antibody assessments
Study: 25841317
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (non-CXL)
Study: 19571762
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block (18 ml of 0.25% bupivacaine)
Study: 19571762
Drug: Combined superficial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined superficial and deep cervical plexus block (14 ml superficial + 4 ml deep of 0.25% bupivacaine)
Study: 17268410
Drug: 5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/day inulin
Study: 17268410
Drug: 8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/day inulin
Study: 17268410
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 8 g/day)
Study: 12716777
Drug: murabutide 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: murabutide 7 mg/day on five consecutive days/week
Study: 12716777
Drug: murabutide 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: murabutide 7 mg/day
Study: 7483792
Drug: TBE vaccine
Normalized name: TBE vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBE vaccine on days 0 and 28
Study: 7483792
Drug: TBE vaccine
Normalized name: TBE vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBE vaccine plus TBE immunoglobulin on day 0 plus TBE vaccine on day 28
Study: 1836920
Drug: Recombinant yeast-derived
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant yeast-derived hepatitis B vaccine
Study: 6123342
Drug: Prazosin (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (not specified dosage)
Study: 21674132
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation with warfarin
Study: 21674132
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents (aspirin or thienopyridine)
Study: 12546741
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (hydrocortisone sodium succinate at 150 mg to 200 mg daily)
Study: 12546741
Drug: Conventional supporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional supporting treatment
Study: 12546741
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (hydrocortisone sodium succinate)
Study: 8883116
Drug: Alfacalcidol treatment
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol treatment (0.25 micrograms twice daily)
Study: 8883116
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 supplementation (500‐1000 units daily)
Study: 3919550
Drug: Molsidomine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (8 to 12 mg orally)
Study: 3919550
Drug: Molsidomine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (8 to 12 mg intravenously)
Study: 3919550
Drug: Molsidomine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (12 mg)
Study: 3919550
Drug: Molsidomine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (12 mg intravenously)
Study: 3919550
Drug: Nitroglycerin (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (1.6 mg sublingually)
Study: 29397899
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day sodium benzoate
Study: 29397899
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day sodium benzoate
Study: 27659931
Drug: Neutral-pH, low-GDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral-pH, low-GDP peritoneal dialysis solution (balance)
Study: 20844595
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg s.c. every other week for 4 weeks
Study: 15917949
Drug: FTY720 (0.25‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (0.25‐2.5 mg/day)
Study: 15917949
Drug: Mofetil mycophenolate
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mofetil mycophenolate (2 mg/day)
Study: 10511062
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg clarithromycin twice a day for 3 days, followed by 20 mg omeprazole
Study: 27993589
Drug: Fixed-combination travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-combination travoprost 0.004%/timolol 0.5% (TTFC)
Study: 25548798
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (30 minutes twice a week)
Study: 24802019
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg FTC capsules alone (Group A)
Study: 24802019
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg FTC combined with 300 mg TDF tablets (Group B)
Study: 24802019
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg FTC plus 300 mg TDF with a high-fat diet (Group C)
Study: 24802019
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 200 mg FTC capsules (Group D)
Study: 24802019
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 200 mg FTC combined with 300 mg TDF tablets (Group E)
Study: 24802019
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of 200 mg FTC plus 300 mg TDF with a high-fat diet (Group F)
Study: 2544640
Drug: Bupivacaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (5 mg/ml)
Study: 2544640
Drug: Lidocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (20 mg/ml)
Study: 20819550
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of gatifloxacin ophthalmic gel vs solution
Study: 9352758
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 0.0625% + fentanyl 3.3 micrograms/ml infusion (Group EPI)
Study: 9352758
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous morphine analgesia (Group PCA)
Study: 3536108
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine eight hourly for three weeks
Study: 29848361
Drug: Febuxostat IR
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat IR 40 mg
Study: 29848361
Drug: Febuxostat IR
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat IR 80 mg
Study: 29848361
Drug: Febuxostat XR
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat XR 40 mg
Study: 29848361
Drug: Febuxostat XR
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat XR 80 mg
Study: 26210304
Drug: Continuous defocused
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous defocused CO2 laser treatment
Study: 26210304
Drug: Symptomatic conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic conservative treatment (oral salve containing lidocaine hydrochloride or systemic diclofenac)
Study: 23041585
Drug: Flat dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat dosing of carboplatin (Arm A)
Study: 23041585
Drug: Intrapatient dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapatient dose escalation of carboplatin (Arm B)
Study: 19458031
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol esters (2.5 g/d)
Study: 19458031
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol esters (2.5 g/d)
Study: 7738618
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy with fadrozole
Study: 7323140
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) at four different doses
Study: 31543299
Drug: ICG-diode laser
Normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-diode laser treatment (PTT group)
Study: 30390647
Drug: Early mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early mass drug administration (MDA) consisting of 3 rounds of a 3-day course of dihydroartemisinin-piperaquine plus a single low dose of primaquine.
Study: 30390647
Drug: Deferred mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred mass drug administration (control group).
Study: 30390647
Drug: Early mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early mass drug administration (MDA).
Study: 26244387
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with baseline viral load at least 100,000 copies/ml
Study: 18449593
Drug: Trimebutine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine (200 mg)
Study: 16513579
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg and hydrochlorothiazide (HCTZ) 12.5 mg
Study: 14510746
Drug: Raftilin HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raftilin HP (5 or 10 g)
Study: 11014404
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg) with quinidine (600 mg)
Study: 11014404
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg) alone
Study: 9001833
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 mL of normal saline)
Study: 6601560
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of 4-aminobenzoic acid (PAB) with meals (240 mg/day)
Study: 6601560
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 80 mg of PAB
Study: 6601560
Drug: Various doses
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various doses of PAB divided throughout the day
Study: 6601560
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of PAB with meals
Study: 28980294
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) infusion (50 mg/kg) after induction of anaesthesia, with two additional doses on postoperative days 1 and 2.
Study: 28980294
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) administered during the same time interval as NAC.
Study: 27981301
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (125 mg, four times a day) for 12 weeks
Study: 25642527
Drug: Patient-centred structured
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centred structured assessment linked to evidence-based treatment algorithms in 15 intervention services.
Study: 23726776
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy / Interpersonal therapy
Study: 11122033
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene gel with narrowband UVB (311 nm)
Study: 11122033
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol with narrowband UVB (311 nm)
Study: 9382235
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine with 0.1 mg of clonidine
Study: 9382235
Drug: Regular intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intramuscular morphine
Study: 1397240
Drug: Induction and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction and consolidation chemotherapy with weekly parenteral vincristine, adriamycin, l‐asparaginase and daily oral prednisone (VAAP)
Study: 1397240
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy for 3 years consisting of daily 6‐mercaptopurine, weekly methotrexate, and monthly intrathecal chemotherapy
Study: 1397240
Drug: Drug intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug intensification comprising either vincristine, adriamycin and l‐asparaginase (VAA) or cyclophosphamide, vincristine, cytosine arabinoside and prednisone (COAP)
Study: 31601541
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of NYVAC vector and gp120 Env protein (T2)
Study: 31601541
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of DNA vector followed by two doses of NYVAC vector and gp120 Env protein (T3)
Study: 31601541
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of DNA vector and gp120 Env protein followed by two doses of NYVAC vector and gp120 Env protein (T4)
Study: 27314448
Drug: Intraperitoneal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal bevacizumab (400 mg absolute)
Study: 20602795
Drug: Bimanual occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual occupational therapy
Study: 17580357
Drug: duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: duloxetine 80 mg/day
Study: 15644669
Drug: 7.5% saline/6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% saline/6% dextran solution (HSD)
Study: 12064330
Drug: 0.8 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg/d phylloquinone for 12 days
Study: 12064330
Drug: 2.0 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/d phylloquinone for 12 days
Study: 12064330
Drug: 4.0 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg/d phylloquinone for 12 days
Study: 7845827
Drug: Propafenone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (600 mg)
Study: 7845827
Drug: Flecainide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (300 mg)
Study: 20177030
Drug: HEC-90 (trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC-90 (trastuzumab plus cyclophosphamide and epirubicin 90 mg/m2)
Study: 20177030
Drug: HEC-60 (trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC-60 (trastuzumab plus cyclophosphamide and epirubicin 60 mg/m2)
Study: 20177030
Drug: EC-90 (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-90 (epirubicin 90 mg/m2 and cyclophosphamide)
Study: 10386423
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 'renal dose' (2.5‐4.0 microg/kg per min) for 48 hours
Study: 8814216
Drug: 495 mg
Normalized name: calcium carbonate 495 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 495 mg daily AA supplement (high AA group)
Study: 8814216
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d of AA (low AA group)
Study: 8814216
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily doses of hexadeuterated RRR‐alpha‐tocopherol acetate (d6‐alphaT)
Study: 1481636
Drug: Intracutaneous sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous sterile water injections
Study: 29186416
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropeptide Y 1.4 mg
Study: 29186416
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropeptide Y 2.8 mg
Study: 29186416
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropeptide Y 4.6 mg
Study: 29186416
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropeptide Y 6.8 mg
Study: 29186416
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropeptide Y 9.6 mg
Study: 16286671
Drug: Astaxanthin (BioAstin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (BioAstin; 1732 mg safflower oil; haematococcus algae extract [contains 4 mg astaxanthin and 480 mg lutein], n = 10)
Study: 16286671
Drug: Placebo (1732
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1732 mg safflower oil, n = 10)
Study: 6820075
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution containing 3.6% total nitrogen as arginine
Study: 6820075
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution containing 10.4% total nitrogen as arginine
Study: 31463257
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg daily)
Study: 26821779
Drug: Low-magnitude mechanical
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-magnitude mechanical stimulation (LMMS) - 10 minutes daily exposure at 30 Hz frequency, 0.3 g peak-to-peak acceleration.
Study: 26821779
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) - 10 minutes daily exposure, no mechanical stimulation.
Study: 20231743
Drug: Menthol counterirritant
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol counterirritant (2 ml applied to anterior knee)
Study: 20231743
Drug: Sham counterirritant
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham counterirritant (2 ml applied to anterior knee)
Study: 18683490
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral probucol (250 mg daily)
Study: 18683490
Drug: Probucol therapy
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol therapy for 7 days before and 6 months after coronary angioplasty